BioDelivery Sciences International Inc. (NASDAQ:BDSI) – Equities research analysts at FBR & Co cut their FY2016 earnings per share (EPS) estimates for BioDelivery Sciences International in a research report issued to clients and investors on Wednesday. FBR & Co analyst E. White now forecasts that the firm will earn ($1.24) per share for the year, down from their prior estimate of ($1.18). FBR & Co currently has a “Buy” rating on the stock. FBR & Co also issued estimates for BioDelivery Sciences International’s Q4 2016 earnings at ($0.27) EPS, FY2017 earnings at ($0.64) EPS and FY2018 earnings at ($0.41) EPS.

Several other research analysts also recently commented on BDSI. Zacks Investment Research downgraded shares of BioDelivery Sciences International from a “buy” rating to a “hold” rating in a report on Wednesday, July 27th. Piper Jaffray Cos. reiterated a “sell” rating and issued a $4.00 target price on shares of BioDelivery Sciences International in a report on Wednesday, August 10th. Cantor Fitzgerald reiterated a “hold” rating on shares of BioDelivery Sciences International in a report on Wednesday, August 10th. Janney Montgomery Scott upgraded shares of BioDelivery Sciences International from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $2.45 to $4.00 in a report on Friday, September 23rd. Finally, Roth Capital set a $7.00 target price on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a report on Friday, October 21st. Two analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $6.57.

Earnings History and Estimates for BioDelivery Sciences International (NASDAQ:BDSI)

BioDelivery Sciences International (NASDAQ:BDSI) opened at 2.00 on Friday. The company’s market cap is $107.53 million. BioDelivery Sciences International has a one year low of $1.70 and a one year high of $6.40. The firm has a 50-day moving average of $2.37 and a 200-day moving average of $2.46.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its earnings results on Wednesday, November 9th. The specialty pharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.26) by $0.04. BioDelivery Sciences International had a negative return on equity of 309.49% and a negative net margin of 93.61%. The business earned $3.60 million during the quarter, compared to the consensus estimate of $3.58 million. During the same period in the prior year, the business earned ($0.39) EPS. The business’s revenue was up 200.0% on a year-over-year basis.

In other news, insider Niraj Vasisht sold 47,000 shares of the business’s stock in a transaction dated Friday, September 23rd. The shares were sold at an average price of $2.43, for a total transaction of $114,210.00. Following the transaction, the insider now owns 73,081 shares in the company, valued at approximately $177,586.83. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Francis E. Odonnell, Jr. sold 100,000 shares of the business’s stock in a transaction dated Friday, September 23rd. The stock was sold at an average price of $2.57, for a total transaction of $257,000.00. The disclosure for this sale can be found here. Insiders own 9.00% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. KCG Holdings Inc. increased its position in BioDelivery Sciences International by 235.8% in the third quarter. KCG Holdings Inc. now owns 39,347 shares of the specialty pharmaceutical company’s stock valued at $106,000 after buying an additional 27,630 shares during the last quarter. NEXT Financial Group Inc boosted its stake in BioDelivery Sciences International by 42.4% in the third quarter. NEXT Financial Group Inc now owns 49,850 shares of the specialty pharmaceutical company’s stock worth $135,000 after buying an additional 14,850 shares during the last quarter. Alpine Partners VI LLC acquired a new stake in BioDelivery Sciences International during the second quarter worth $147,000. Krilogy Financial LLC acquired a new stake in BioDelivery Sciences International during the second quarter worth $164,000. Finally, Bank of New York Mellon Corp boosted its stake in BioDelivery Sciences International by 9.9% in the third quarter. Bank of New York Mellon Corp now owns 62,945 shares of the specialty pharmaceutical company’s stock worth $170,000 after buying an additional 5,677 shares during the last quarter. Institutional investors own 60.44% of the company’s stock.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

5 Day Chart for NASDAQ:BDSI

Receive News & Stock Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related stocks with our FREE daily email newsletter.